Search

Displaying results 761 - 770 of 2744 in total
  1. Drug

    Rhizopus stolonifer

    go.drugbank.com/drugs/DB10814
    Approved

    Rhizopus stolonifer is a fungus which can provoke allergic reactions. Rhizopus stolonifer extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS329906
  2. Drug

    Penicillium chrysogenum var. chrysogenum

    go.drugbank.com/drugs/DB10439
    Approved

    Penicillium chrysogenum var. chrysogenum is a fungus which can provoke allergic reactions. Penicillium chrysogenum var. chrysogenum extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS333938
  3. Drug

    Bupranolol

    go.drugbank.com/drugs/DB08808
    Experimental

    It does not have intrinsic sympathomimetic activity (ISA), but does have strong membrane stabilizing activity.

  4. Drug

    Tenecteplase

    go.drugbank.com/drugs/DB00031
    ApprovedInvestigational

    Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 1...

  5. Drug

    Zanamivir

    go.drugbank.com/drugs/DB00558
    ApprovedInvestigational

    A guanido-neuraminic acid that is used to inhibit neuraminidase.

  6. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. While traditional disease-modifying immunotherapeutics are administered by su...

  7. Drug

    Ravulizumab

    go.drugbank.com/drugs/DB11580
    ApprovedInvestigational

    Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor...

  8. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for hemorrhage and thromboembolic events...

  9. Drug

    Abatacept

    go.drugbank.com/drugs/DB01281
    ApprovedInvestigational

    Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structu...

  10. Drug

    Brentuximab vedotin

    go.drugbank.com/drugs/DB08870
    ApprovedInvestigational

    [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse … [L1737] The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care.